micrographic surgery
Recently Published Documents





2022 ◽  
Vol 63 (Suppl) ◽  
pp. S112
Yeongjoo Oh ◽  
Hye Min Kim ◽  
Soon Won Hong ◽  
Eunah Shin ◽  
Jihee Kim ◽  

2021 ◽  
Vol 50 (12) ◽  
pp. 922-923
Wen Yang Benjamin Ho ◽  
Xiahong Zhao ◽  
Wee Ping Melissa Tan

Maria Charalambides ◽  
Basil Yannoulias ◽  
Nabiah Malik ◽  
Jasmine Mann ◽  
Perin Celebi ◽  

2021 ◽  
Vol Publish Ahead of Print ◽  
Christine N. Schafer ◽  
Eva A. Hurst ◽  
Ilana S. Rosman ◽  
M. Laurin Council

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6146
Christina Fotiadou ◽  
Zoe Apalla ◽  
Elizabeth Lazaridou

Basosquamous carcinoma is a rare, aggressive non-melanoma skin cancer with features that lie between those of basal cell carcinoma and squamous cell carcinoma. A lot of controversy has been raised around the classification, pathogenesis, histologic morphology, biologic behavior, prognosis and management of this tumor. This is a narrative review based on an electronic search of articles published in PubMed in English language which had in their title the terms “basosquamous carcinoma” and/or “metatypical carcinoma of the skin”. The aim of this review was to summarize and evaluate current data regarding epidemiology, clinical presentation, dermoscopic and histopathologic characteristics, as well as the genetics and management of BSC, in order to shed some more light onto this intriguing entity. As a conclusion, dermoscopy, deep incisional biopsies and immunohistologic techniques (Ber-EP4) should be applied in clinically suspicious lesions in order to achieve an early diagnosis and better prognosis of this tumor. Surgical treatments, including wide excision and Mohs’ micrographic surgery, remain the treatment of choice. Finally, vismodegib, a Hedgehog pathway inhibitor, must be thoroughly investigated, with large controlled trials, since it may offer an alternative solution to irresectable or difficult-to-treat, locally advanced cases of basosquamous carcinoma.

Sign in / Sign up

Export Citation Format

Share Document